

A RESOLUTION to encourage the United States Food and Drug Administration to study the use of medical marijuana.

WHEREAS, modern medical research indicates that there are beneficial uses of medical marijuana in treating or alleviating the pain, nausea, and other symptoms associated with a variety of debilitating medical conditions, including cancer, multiple sclerosis, and HIV/AIDS; and

WHEREAS, medical marijuana has many currently accepted medical uses in the United States, having been recommended by thousands of licensed physicians to more than 500,000 patients in the states with medical marijuana laws; and

WHEREAS, medical marijuana's utility has been recognized by a wide range of medical and public health organizations, including the American Academy of HIV Medicine, the American College of Physicians, the American Nurses Association, the American Public Health Association, the Leukemia & Lymphoma Society, and many others; and

WHEREAS, the states of Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, and Washington, as well as the District of Columbia, have removed state-level criminal penalties from the medical use and cultivation of medical marijuana; and

WHEREAS, studies are currently being conducted by the Epilepsy Foundation in Colorado that have showed positive outcomes for children with severe cases of epilepsy with the use of "Charlotte's Web", an oil made from marijuana plants. The medication has high levels of cannabidiol (CBD) the component believed to be effective in controlling seizure activity; and

WHEREAS, there have never been intensive studies into the benefits, side effects, drug interactions, dosages, and other aspects of medical marijuana;

NOW, THEREFORE,

*Be it resolved by the House of Representatives of the General Assembly of the Commonwealth of Kentucky:*

➔Section 1. This honorable body encourages the United States Congress to authorize and direct the Food and Drug Administration to study the benefits, side effects, drug interactions, dosages, and other aspects of medical marijuana and evaluate current efforts regarding public information and awareness.

➔Section 2. The Clerk of the House of Representatives is directed to transmit a copy of this Resolution to the President of the United States; the Majority Leader of the United States Senate; the Speaker of the United States House of Representatives; the members of Kentucky's congressional delegation; and the Secretary of the United States Food and Drug Administration.